{"title":"Cardiovascular-Kidney-Metabolic Syndrome: Development of an ICD-10-CM Coding Framework.","authors":"Minzhe Zhao, Junhao Zhang, Huiyun Wang, Chongjun Xu, Jiahui Li, Chenghua Li, Xuemei He, Xueying Zheng","doi":"10.2196/91827","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-Kidney-Metabolic (CKM) syndrome is a multisystem construct describing the intertwined progression of cardiometabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD). The American Heart Association (AHA) proposed CKM stages (0-4) for risk stratification and prevention. However, CKM lacks a single ICD-10-CM code, which hinders standardized stage identification in EHRs and claims data.</p><p><strong>Objective: </strong>To develop an AHA-aligned ICD-10-CM coding framework as an implementation template that operationalizes CKM stages 0-4 for reproducible cohort identification and stage-based analyses in real-world data.</p><p><strong>Methods: </strong>We mapped American Heart Association CKM stages (0-4) to ICD-10-CM diagnosis code sets using FY2026 conventions, code-set engineering best practices, and clinician review. To improve reproducibility, we defined a hierarchical staging algorithm, co-occurrence rules, and recommended lookback and encounter-confirmation thresholds. Stage 3 includes guidance for EHR-enhanced ascertainment and claims-only proxies.</p><p><strong>Results: </strong>We provide stage-specific ICD-10-CM code sets for CKM stages 0-4. Stage 1 captures excess or dysfunctional adiposity or prediabetes. Stage 2 captures established metabolic disease and earlier-stage CKD. Stage 3 captures subclinical cardiovascular injury or very high-risk CKD. Stage 4 captures overt clinical CVD events, with or without kidney failure.</p><p><strong>Conclusions: </strong>This implementation framework enables transparent, reproducible CKM staging in real-world datasets and supports stage-based epidemiologic and health-system applications. Empirical validation and local implementation testing are needed prior to clinical deployment.</p><p><strong>Clinicaltrial: </strong></p>","PeriodicalId":52371,"journal":{"name":"JMIR Diabetes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/91827","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiovascular-Kidney-Metabolic (CKM) syndrome is a multisystem construct describing the intertwined progression of cardiometabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD). The American Heart Association (AHA) proposed CKM stages (0-4) for risk stratification and prevention. However, CKM lacks a single ICD-10-CM code, which hinders standardized stage identification in EHRs and claims data.
Objective: To develop an AHA-aligned ICD-10-CM coding framework as an implementation template that operationalizes CKM stages 0-4 for reproducible cohort identification and stage-based analyses in real-world data.
Methods: We mapped American Heart Association CKM stages (0-4) to ICD-10-CM diagnosis code sets using FY2026 conventions, code-set engineering best practices, and clinician review. To improve reproducibility, we defined a hierarchical staging algorithm, co-occurrence rules, and recommended lookback and encounter-confirmation thresholds. Stage 3 includes guidance for EHR-enhanced ascertainment and claims-only proxies.
Results: We provide stage-specific ICD-10-CM code sets for CKM stages 0-4. Stage 1 captures excess or dysfunctional adiposity or prediabetes. Stage 2 captures established metabolic disease and earlier-stage CKD. Stage 3 captures subclinical cardiovascular injury or very high-risk CKD. Stage 4 captures overt clinical CVD events, with or without kidney failure.
Conclusions: This implementation framework enables transparent, reproducible CKM staging in real-world datasets and supports stage-based epidemiologic and health-system applications. Empirical validation and local implementation testing are needed prior to clinical deployment.